Should You Buy Walmart Stock After a 14% Decline in Six Months?

Walmart shares have fallen 14.3% over six months, underperforming the S&P 500's 12.2% gain, as pharmacy deflation, consumer affordability pressure, price investments and higher operating costs weigh on near-term earnings. Current- and next-fiscal-year EPS consensus estimates have declined over the past 30 days, while WMT still trades at a 34.25x P/E, above its 24.9x five-year median. Long-term growth remains supported by e-commerce, advertising, marketplace, membership and international expansion, but the article maintains a Hold/neutral stance pending improved estimates or a more attractive valuation.

Analysis

The key underwriting issue is not traffic resilience but the timing mismatch between price investment/capex and monetization of higher-margin digital adjacencies. WMT can continue taking share while EPS disappoints if grocery deflation, pharmacy reimbursement pressure and fulfillment depreciation absorb gross-profit gains; at a premium multiple, even modest estimate cuts can drive disproportionate de-rating. This makes the next 1-3 months primarily an estimate-revision and margin-guidance trade rather than a read-through on long-term competitive position.

Competitive effects are asymmetric. WMT’s willingness to reinvest savings into shelf prices raises the hurdle for DG, whose lower-income customer base is more exposed to discretionary-budget stress and whose smaller basket provides less room to offset freight, shrink and labor. TGT is more vulnerable than WMT to a promotion-led category environment, but its lower valuation means incremental operating stabilization can produce greater multiple upside; COST remains the cleanest defensive operator but offers limited protection from valuation compression if consumer-staples-style earnings growth is insufficient to support its premium.

Contrarian view: the market may be over-focusing on reported pharmacy sales and underweighting the strategic value of WMT’s local fulfillment density. If management demonstrates that advertising, marketplace and delivery economics are funding price investment rather than merely masking retail-margin erosion, the stock can rerate over 6-18 months. Falsification is clear: another earnings cycle with U.S. ex-pharmacy sales deceleration, incremental operating-margin pressure, or further FY EPS-guide cuts would argue that share gains are being bought rather than monetized.

Key Decisions for Investors

• Remain neutral WMT into the next earnings print; initiate a long only after consensus FY EPS stops declining and management confirms stable or improving operating-margin cadence. Target 10-15% upside over 6-12 months from multiple stabilization; exit on a further full-year EPS-guide reduction or evidence of ex-pharmacy comp deterioration.
• Express near-term competitive pressure through a 1-3 month long WMT / short DG pair, sized beta-neutral. WMT’s grocery mix, omnichannel scale and higher-income customer gains should be more resilient, while DG has greater exposure to price-sensitive baskets and fixed-cost deleverage; cover if DG demonstrates sustained positive traffic and margin recovery.
• Do not chase TGT’s recent relative strength without evidence that promotions are not eroding gross margin. Use an earnings-related alert: if TGT maintains margin guidance while inventory and discretionary-category trends improve, rotate part of WMT exposure into TGT for higher valuation-recovery optionality.
• Monitor retail earnings revisions and gasoline prices weekly. A renewed fuel spike would intensify value-channel traffic but likely extend WMT price-investment duration; that is bullish relative to DG/TGT but not necessarily bullish absolute WMT until margin expectations reset.